Document:

EX-10.32

 Exhibit 10.32 

 

					
	

	 		  	 Starry, Inc.

38 Chauncy Street

Suite 200

Boston, MA 02111

 September 3, 2020 

Via Hand Delivery - Personal and Confidential 

Gregg Bien 
 3688 Waples Court 

Oakton, VA 22124 
 Dear Gregg, 

As discussed, your employment with Starry, Inc. (“Starry” or the “Company”) shall terminate effective
September 21, 2020. This letter (the “Agreement”) summarizes the terms of your separation from employment and establishes an amicable arrangement under which you release the Company from any and all claims, and, in return, you
receive severance pay and other benefits. 
 1. Final Payments; Benefits Cessation: 

(a) Final Payments: Your employment from the Company will terminate on September 21, 2020 (the “Separation Date”).
As of the Separation Date, your salary will cease and you no longer will be entitled to the payment of base salary, bonus, commission, or any other form of compensation, except as set forth in this Agreement. On the Separation Date, the Company
shall pay to you all earned but unpaid base salary up to and through the Separation Date. In addition, the Company will reimburse you for all pre-approved and appropriately documented business expenses in
accordance with Company policy, provided that you submit all documentation of any such expenses within 10 days of the Separation Date and in accordance with applicable Company policy. You will receive these payments regardless of whether you execute
this Agreement. 
 (b) Benefits Cessation: As of the Separation Date, any entitlement you have or might have under a Company-provided benefit plan, program or practice shall terminate, except as required by law, as otherwise described below, or unless such benefits already have terminated in accordance with the applicable plan
terms and conditions. You will receive under separate cover benefit continuation information pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), as amended. 

(c) Equity: Any vested equity grants shall be governed by the applicable agreement between you and the Company and the Company’s
Stock Plan. 
 2. Consideration: In exchange for, and in consideration of your executing and complying with this Agreement and any other
agreement with Starry that survives the termination of your employment and conditioned upon your continued professionalism in transitioning your duties in a timely and satisfactory manner, the Company will provide you with the following after the
Effective Date (as defined in Section 11 below): 

 Gregg Bien 

September 2, 2020 
  Page 
 2
 
  

 (a) Severance Payments: The Company will pay you a lump sum payment of $75,000.00,
minus all applicable state and federal taxes and other withholdings. This payment will be made to you on the first regularly scheduled payday that is on or after 30 days following the Effective Date as defined in Section 12, below. Neither the
Company nor you shall have the right to accelerate or defer the delivery of such payment or any benefits provided hereunder except to the extent specifically permitted or required by Section 409A of the Internal Revenue Code, as amended. 

(b) Payment of COBRA Premiums: Subject to the terms and conditions provided for in COBRA, and provided you have timely and properly
elected COBRA coverage in accordance with the Company’s COBRA election procedures and if you properly execute this Agreement, the Company will pay full COBRA premium until December 31, 2020 or such earlier time as you (i) obtain
alternate medical insurance or (ii) become ineligible for COBRA benefits. You will be responsible for your COBRA premiums after December 31, 2020. 

(c) Acknowledgement of Consideration to Support Agreement: You expressly acknowledge and agree that the payments and benefits provided
to you under this Section 2 are benefits to which you are not otherwise entitled to receive and are being given to you solely in exchange for your promise to be bound by the terms of this Agreement. 

3. Taxes: All payments set forth in this Agreement shall be subject to all applicable federal, state and/or local withholding and/or
payroll taxes, and the Company may withhold from any amounts payable to you (including any amounts payable pursuant to this Agreement) in order to comply with such obligations. 

4. General Release of Claims; Accord and Satisfaction: 

(a) General Release: You hereby agree that by signing this Agreement and accepting the payments to be provided to you, and other good
and valuable consideration provided for in this Agreement, the receipt of which you hereby acknowledge, you, for yourself and on behalf of your representatives, agents, estate, heirs, successors and assigns (“You”), hereby release
and waive your right to assert any form of legal claim against the Released Parties (defined in Section 4(e) below) whatsoever for any alleged action, inaction or circumstance, whether existing or contingent, known or unknown, suspected or
unsuspected, existing or arising from the beginning of time through the Effective Date. 
 What this general release covers: Your
waiver and release herein is intended to bar any form of legal claim, cause of action, lawsuit, charge, complaint or any other form of action (jointly referred to as “Claims”) against the Company seeking any form of relief
including, without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages or any other form of monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages,
emotional distress damages, punitive damages, attorneys’ fees and any other costs) against the Company, for any alleged action, inaction or circumstance existing or arising through the Effective Date. 

 Gregg Bien 

September 2, 2020 
  Page 
 3
 
  

 Without limiting the foregoing general waiver and release, You specifically waive and release
the Company from any Claim arising from or related to your employment relationship with the Company or the termination thereof, including, without limitation: 

(i) Claims under any federal, state or local statute, regulation or executive order (as amended through the Effective Date)
relating to employment, discrimination (including discrimination on the basis of race, color, religion, creed, sex, sex harassment, sexual orientation, age, gender identity, marital status, familial status, pregnancy, national origin, ancestry,
alienage, handicap, disability, present or past history of mental disorders or physical disability, veteran’s status, candidacy for or activity in a general assembly or other public office, or constitutionally protected acts of speech), fair
employment practices, retaliation or other terms and conditions of employment, including but not limited to the Age Discrimination in Employment Act and Older Workers Benefit Protection Act (29 U.S.C. § 621 et seq.), the Civil Rights Acts
of 1866 and 1871, Title VII of the Civil Rights Act of 1964 and the Civil Rights Act of 1991 (42 U.S.C. § 2000e et seq.), the Equal Pay Act (29 U.S.C. § 201 et seq.), the Americans With Disabilities Act (42 U.S.C.
§ 12101 et seq.), the Immigration Reform and Control Act (8 U.S.C. § 1101 et seq.), as well as the specific state statutes noted in Exhibit A; 

(ii) Claims under any federal, state or local statute, regulation or executive order (as amended through the Effective Date)
relating to leaves of absence, layoffs or reductions-in-force, wages, hours, or other terms and conditions of employment, including but not limited to the National Labor
Relations Act (29 U.S.C. § 151 et seq.), the Family and Medical Leave Act (29 U.S.C. § 2601 et seq.), the Employee Retirement Income Security Act of 1974 (29 U.S.C. § 1000 et seq.), COBRA (29 U.S.C. § 1161 et
seq.), the Fair Labor Standards Act (29 U.S.C. § 201 et seq.), the Occupational Safety and Health Act (29 U.S.C. § 651 et seq.), as well as the specific state statutes noted in Exhibit A; 

(iii) Claims under any federal or state common law theory, including, without limitation, wrongful discharge, breach of express
or implied contract, promissory estoppel, unjust enrichment, breach of a covenant of good faith and fair dealing, violation of public policy, defamation, interference with contractual relations, intentional or negligent infliction of emotional
distress, invasion of privacy, misrepresentation, deceit, fraud, negligence, or any claim to attorneys’ fees under any applicable statute or common law theory of recovery; 

(iv) Claims under any federal, state or local statute, regulation or executive order (as amended through the Effective Date)
relating to whistleblower protections, violation of public policy, or any other form of retaliation or wrongful termination, including but not limited to the Sarbanes-Oxley Act of 2002, any similar federal,
state or local statute, as well as the specific state statutes noted in Exhibit A; 
 (v) Claims
under any Company compensation, benefit, stock option, incentive compensation, bonus, restricted stock, and/or equity plan, program, policy, practice or agreement; or 

 Gregg Bien 

September 2, 2020 
  Page 
 4
 
  

 (vi) Any other Claim arising under other federal, state or local law. 

(b) Interpretation; Collective/Class Action Waiver: The foregoing
release-of-claims provision set forth in Section 4(a) shall be given the broadest possible interpretation permitted by law. The enumeration of specific claims
therein shall not be interpreted to exclude any other claims not specifically enumerated therein. With respect to any claim released under this Agreement or any claim is not subject to release, to the extent permitted by law, you waive any right or
ability to be a class or collective representative or to otherwise participate in any putative or certified class, collective or multi-party action or proceeding based on such a claim in which Starry or any of
the Release Parties is a party. 
 (c) Exclusions from General Release: You and the Company acknowledge and agree that this Release
Agreement shall not affect the rights and responsibilities of the Equal Employment Opportunity Commission (the “EEOC”), the Securities and Exchange Commission (“SEC”), the Department of Justice
“DOJ”), the National Labor Relations Board (“NLRB”) or any similar federal or state agency to enforce applicable laws, and further acknowledge and agree that this Release Agreement shall not be used to justify
interfering with your protected right to file a charge, make disclosures or participate in an investigation or proceedings conducted by the EEOC, SEC, DOJ, NLRB or similar federal or state agency. Accordingly, nothing in this Release Agreement shall
preclude you from filing a charge with, making a protected disclosure to or participating in any manner in an investigation, hearing or proceeding conducted by the EEOC, SEC, DOJ, NLRB or similar federal or state agency, but, to the fullest extent
permissible under applicable law, you hereby waive any and all rights to recover any damages under, or by virtue of, any such investigation, hearing or proceeding. Nothing in this Release Agreement shall affect or be used to interfere with your
protected right to contest in any court, under the Older Workers’ Benefit Protection Act, or like statute or regulation, the validity of the waiver of rights under the ADEA set forth in this Release Agreement. Any right or claim that cannot be
waived as a matter of law and your right to enforce this Agreement also are excluded from the release of claims set forth in Section 4(a). As such, you are not releasing your right to enforce the terms of this Agreement, your rights under the
Company’s 401(k) plan, your right to apply for unemployment compensation, and/or or your right to challenge the validity or enforceability of your waiver of ADEA rights pursuant to this Agreement. 

(d) Accord and Satisfaction: The payments in Sections 1 and 2 shall be complete and unconditional payment, settlement, accord
and/or satisfaction with respect to all obligations and liabilities of the Released Parties to You including, without limitation, all claims for back wages, salary, vacation pay, sick pay, notice pay, bonuses, commissions or other incentive
compensation, severance pay, all other forms of compensation or benefits, attorney’s fees, or other costs or sums. 
 (e) Definition
of Released Parties: As used in this Agreement, “Released Parties” shall mean: Starry; (ii) all of Starry’s past, present, and future subsidiaries, parents, affiliates and divisions; (iii) all of Starry’s
successors and/or assigns; (iv) all of Starry’s past, present, and future officers, directors, managers, employees, shareholders, owners, attorneys, agents, insurers, employee benefit plans (including such plans’ administrators,
trustees, fiduciaries, record-keepers, insurers and reinsurers), and legal representatives (all both individually, in their capacity acting on Starry’s behalf and in their official capacities); and
(v) all persons acting by, through, under, or in concert with any of the entities or persons listed in subsections (i)-(iv). 

 Gregg Bien 

September 2, 2020 
  Page 
 5
 
  

 5. Waiver of Rights and Claims Under the Age Discrimination in Employment Act of 1967:
Because you are 40 years of age or older, you are being informed that you have or may have specific rights and/or claims related to age discrimination under the Age Discrimination in Employment Act of 1967 (ADEA) and you agree that: 

(a) in consideration for the amounts described in Section 2 of this Agreement, which you are not otherwise entitled to receive, you
specifically and voluntarily waive such rights and/or claims under the ADEA you might have against the Releasees to the extent such rights and/or claims arose prior to the date this Agreement was executed; 

(b) you understand that rights or claims under the ADEA which may arise after the date this Agreement is executed are not waived by you; 

(c) you are advised to consult with or seek advice from an attorney of your choice or any other person of your choosing prior to executing this
Agreement, that you have at least 21 days within which to consider the terms of this Agreement, and that such 21-day review period will not be affected or extended by any revisions, whether material or
immaterial, that might be made to this Agreement; 
 (d) in entering into this Agreement you are not relying on any representation, promise
or inducement made by the Company or its attorneys with the exception of those promises described in this document; and 
 (e) you may revoke
this Agreement for a period of seven (7) days following your execution hereof and all rights and obligations of both parties under this Agreement shall not become effective or enforceable until the seven (7) day revocation period has
expired. 
 6. Covenant Not to Sue: A “covenant not to sue” is a legal term that means you promise not to file a lawsuit in
court. It is different from the release of claims in Sections 4(a) and 5(a) above. Besides waiving and releasing the claims covered by Sections 4(a) and 5(a), you further agree never to sue the Released Parties in any forum based on the
claims, laws or theories covered by the release language in Sections 4(a) and 5(a). You represent and warrant that you have not filed any complaints, charges, or claims for relief against the Released Parties with any local, state or federal
court or administrative agency, with the sole exception of your right to pursue a state unemployment claim. Notwithstanding this Covenant Not To Sue, you may bring a claim to enforce the terms of this Agreement, to pursue state unemployment
benefits, or to challenge the validity of the ADEA waiver described in Section 5. Except as set forth in Section 4(c) or as permitted pursuant to this Section 6, in the event that you institute any other action, that claim shall be
dismissed upon the presentation of this Agreement and you shall reimburse the Company for all legal fees and expenses incurred in defending such claim and obtaining its dismissal. Notwithstanding the foregoing, should you bring an action to
challenge the validity of the release and waiver of ADEA claims described in Section 5, the Company acknowledges that it will not be entitled to recover costs and expenses (including attorneys’ fees) incurred in defense of the validity of
the release and waiver of ADEA claims. 

 Gregg Bien 

September 2, 2020 
  Page 
 6
 
  

 7. Company Files, Documents and Other Property: You agree to return to the Company
within seven days of the Separation Date, all Company property and materials (copies and originals), including but not limited to, all hardware, personal computers, laptops, CDs/DVDs, intangible information stored on CDs/DVDs, software programs and
data compiled with the use of those programs, software passwords or codes, tangible copies of trade secrets and confidential information, cellular phones, smart phones, charge/credit cards, identification cards, building keys and passes, manuals,
names and addresses of all Company customers, partners, and potential customers and partners, customer lists, customer files, customer contracts, sales information, memoranda, sales brochures, business or marketing plans, reports, projections, and
any and all other information or property previously or currently held or used by you that is or was related to your employment with the Company (“Property”). You agree that if you discover any other Property, including any
proprietary materials, in your possession after the Separation Date, you immediately will notify the Company and arrange for their prompt return. In addition, you must delete and finally purge any duplicates of files or documents that may contain
Company information from any non-Company computer or other device that remains in your possession after the Separation Date. 

8. No Liability or Wrongdoing: You understand and agree that this Agreement constitutes a final compromise of the claims released
thereby, and is not an admission by the Released Parties that any such claims exist and/or of liability by the Released Parties with respect to such claims. Nothing in this Agreement, nor any of the proceedings connected with it, is to be construed
as, offered as, received as, or deemed to be evidence of an admission by the Released Parties of any liability or unlawful conduct whatsoever, and each of the Released Parties expressly deny any such liability or wrongdoing. 

9. Future Conduct: 
 (a)
Existing Agreements: You confirm the existence and continued validity of the Employee Confidentiality and IP Assignment Agreement, which you signed in connection with your employment with the Company (the “Nondisclosure
Agreement”). You agree that your obligations under the Nondisclosure Agreement expressly survive the cessation of your employment. If you fail to abide by your obligations under the Nondisclosure Agreement, the Company immediately may
terminate all severance benefits in Section 2, or seek repayment of such amounts, in addition to seeking all other legal and equitable relief. For your reference, a copy of your Nondisclosure Agreement is enclosed with this letter. 

(b) Non-disparagement: You agree not to take any action or make any statement, written or
oral, which disparages or criticizes the Released Parties, their officers, directors, investors or employees, the Released Parties’ business practices, or which disrupts or impairs their normal operations, including actions that would
(i) harm the Released Parties’ reputation with their current and prospective clients, business partners, or the public; or (ii) interfere with existing contracts or employment relationships with current and prospective clients,
business partners or Released Parties’ employees. The Company agrees not to, and agrees to use its reasonable best efforts to cause its directors and officers not to, take any action or make any statement, written or oral, which disparages or
criticizes you, including actions that harm your reputation with prospective clients, employers, business partners or the public. 

 Gregg Bien 

September 2, 2020 
  Page 
 7
 
  

 (c) Confidentiality of this Agreement: You shall maintain confidentiality concerning
this Agreement, including the substance, terms, existence and/or any discussions relating to this Agreement. Except as required pursuant to legal process, you will not discuss the same with anyone except your immediate family and accountants or
attorneys when such disclosure is necessary for them to render professional services. Nothing herein shall prohibit or bar you from providing truthful testimony in any legal proceeding or in communicating with any governmental agency or
representative or from making any truthful disclosure required, authorized or permitted under law; provided however, that in providing such testimony or making such disclosures or communications, you will use your best efforts to ensure that this
Section is complied with to the maximum extent possible. 
 (d) Advance Notice: Should you be called to testify about the terms
of this Agreement and/or the Company’s confidential, proprietary and/or trade secret information, you agree to join the Company in seeking a confidentiality or protective order in the form sought by the Company. You agree to give reasonable
notice to the Company of any and all attempts by third parties to compel disclosure of any confidential information (as referred to in your Nondisclosure Agreement), or the terms of this Agreement, or to require you to testify in any matter
concerning the Company, this Agreement and/or the Released Parties. Please direct such notice to the Company’s Senior Vice President and General Counsel, William Lundregan. You shall provide such reasonable notice in writing at least ten
business days before compliance with any subpoena or order, but if the subpoena or order requires compliance within less than ten business days, you shall provide such written notice, or if impractical, shall provide telephonic notice, within five
business days after receiving notice that an attempt will be or has been made to compel your testimony or your disclosure of the Company’s confidential, proprietary and/or trade secret information. 

(e) Required Disclosure: You are hereby notified in accordance with the Defend Trade Secrets Act of 2016 that you will not be held
criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney solely for
the purpose of reporting or investigating a suspected violation of law, or that is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If you file a lawsuit for retaliation against the Company for
reporting a suspected violation of law, you may disclose the Company’s trade secrets to your attorney and use the trade secret information in the court proceeding if you file any document containing the trade secret under seal, and do not
disclose the trade secret, except pursuant to court order. 
 (f) Breach; Remedies: If you breach this Agreement or the Nondisclosure
Agreement, you agree that (i) the Company shall be relieved of its obligations to make the payments under Section 2, (ii) if such payment or payments already have been made, you agree to repay them to the Company, and (iii) the
Company shall be entitled to recover its attorneys’ fees and costs incurred in enforcing its rights under this Agreement, to the extent such recovery is not prohibited by law. Such an action by the Company shall not affect the release
provisions herein. This remedy shall be, in addition to, and not as an alternative to, any other remedies at law or in equity available to the Company. 

 Gregg Bien 

September 2, 2020 
  Page 
 8
 
  

 10. Representations and Governing Law: 

(a) Integration: This Agreement sets forth the complete and sole agreement between the parties and supersedes any and all other
agreements or understandings, whether oral or written, express or implied, except for the Nondisclosure Agreement and any written equity-related agreement, which remain in full force and effect in accordance
with their terms. This Agreement may not be changed or rescinded except upon the express written consent of both you and an authorized Company officer. Any waiver of any provision of this Agreement shall not constitute a waiver of any other
provision of this Agreement unless expressly so indicated otherwise. The language of all parts of this Agreement shall in all cases be construed as a whole according to its fair meaning and not strictly for or against any of the parties. 

(b) Governing Law and Choice of Venue; Waiver of Jury Trial: This Agreement shall be deemed to be made and entered into in the
Commonwealth of Massachusetts. This Agreement and any claims arising out of this Agreement (or any other claims arising out of the relationship between the parties) shall be governed by and construed in accordance with the laws of the Commonwealth
of Massachusetts and shall in all respects be interpreted, enforced and governed under the internal and domestic laws, without giving effect to the principles of conflicts of laws of such Commonwealth. Any claims or legal actions by one party
against the other shall be commenced and maintained in any state or federal court located in such Commonwealth, and you hereby submit to the jurisdiction and venue of any such court. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO
TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 (c)
Severability: If any provision of this Agreement, or part thereof, is held invalid, void or voidable as against public policy or otherwise, the invalidity shall not affect other provisions, or parts thereof, which may be given effect without
the invalid provision or part. To this extent, the provisions, and parts thereof, of this Agreement are declared to be severable. 
 (d)
Assignment: You shall not assign this Agreement. The Company may assign this Agreement. The benefits of this Agreement shall inure to the successors and assigns of the Company and the Released Parties and to your successors. 

(e) Acknowledgment of Company’s Compliance with Applicable Law: You represent that: 

(i) you have not been subject to any retaliation or any other form of adverse action by the Released Parties for any action
taken by you as an employee or resulting from your exercise of, or attempt to exercise, any statutory rights recognized under federal, state or local law; 

 Gregg Bien 

September 2, 2020 
  Page 
 9
 
  

 (ii) the Released Parties have satisfied in full all obligations they ever
had regarding leaves of absence and other time off of any kind (including, but not limited to, short-term disability leave, family medical leave, military leave, vacations, meal and rest periods, sick and
personal days, and personal leave), and you have not suffered any adverse employment action as a result of seeking or taking any such leave of absence or time off; and 

(iii) you have no known workplace injuries or occupational diseases, have not sustained any disabling injury and/or
occupational disease that have resulted in a loss of wage earning capacity during your employment, and have no personal injury and/or occupational disease that has been contributed to, or aggravated or accelerated in a significant manner by, your
employment or separation from employment. 
 11. Review Period; Effective Date: As set forth in Section 5, you will have the
opportunity to review and consider this Agreement for up to twenty-one (21) days before signing it. In addition, you have the right to revoke your execution of this Agreement at any time during the seven
(7) days immediately following the date on which you sign it. For such a revocation to be effective, it must be delivered so that the undersigned person receives it in-hand or via fax at the number below
at or before the expiration of the seven (7) day revocation period. This Agreement shall become effective on the first day following the expiration of the seven (7) day revocation period (the “Effective Date”). Because
this Agreement includes a waiver and release of your rights, the Company advises you to consult with an attorney prior to executing it. 
 If you wish to
accept this Agreement, please sign and date the Agreement below and return it to my attention by E-Mail at ck@starry.com. Also, please forward the original, signed document to my attention at
Starry, Inc., 38 Chauncy Street, Suite 200, Boston, MA 02111 within the time period described above. If you do not return a signed Agreement prior to the expiration of the 21-day review period, i.e., on or
before September 24, 2020, then this offer of severance shall expire. 
 We wish you every success for the future. 

 

	
	Very truly yours,
	
	 /s/ Chaitanya Kanojia

	Starry, Inc.
	Chaitanya Kanojia
	President
	Enclosures

 Gregg Bien 

September 2, 2020 
  Page 
 10
 
  

 PLEASE REVIEW CAREFULLY 

YOUR EMPLOYMENT BY THE COMPANY WILL BE TERMINATING. SUCH TERMINATION WILL NOT BE AFFECTED BY YOUR ACCEPTANCE OR FAILURE TO ACCEPT THIS AGREEMENT. IF YOU DO
NOT ACCEPT THIS AGREEMENT, YOU WILL NOT RECEIVE THE PAYMENTS AND BENEFITS AS SET FORTH IN SECTION 2. 
 THIS AGREEMENT CONTAINS A RELEASE OF CERTAIN
LEGAL RIGHTS YOU MAY HAVE. YOU ARE ADVISED TO CONSULT WITH AN ATTORNEY REGARDING THIS AGREEMENT BEFORE SIGNING IT. 
 PLEASE NOTE THAT THE RELEASE
AND WAIVER OF CLAIMS IN SECTIONS 4 AND 5 DO NOT EXTEND TO RIGHTS OR CLAIMS THAT ARISE AFTER THE DATE THE WAIVER IS EXECUTED. 
 *****

 YOU REPRESENT THAT YOU HAVE READ THE FOREGOING AGREEMENT, FULLY UNDERSTAND ITS TERMS AND CONDITIONS AND ARE VOLUNTARILY EXECUTING THE SAME. 

IN ENTERING INTO THIS AGREEMENT, YOU DO NOT RELY ON ANY REPRESENTATION, PROMISE OR INDUCEMENT MADE BY THE RELEASED PARTIES WITH THE EXCEPTION OF THE
CONSIDERATION IN THIS DOCUMENT. 
  

					
	ACCEPTED:	 		 	
			
	 /s/ Gregg Bien
	 		 	Date: September 3, 2020
	Gregg Bien	 		 	

 I agree and certify that this digital signature is an authorized and legally binding signature as though it was signed under
seal. 

 Gregg Bien 

September 2, 2020 
  Page 
 11
 
  

 As referenced in Section 4, the General Release of Claims broadly applies to all state
statutes generally relating to the claims identified and/or referenced in Section 4, which includes (without limitation) the following state statutes: 

Massachusetts: any Massachusetts state or local laws, administrative rules or regulations respecting employment, including but not
limited to, the Massachusetts Wage Payment Act (M.G.L. c. 149, § 148), the Massachusetts Minimum Fair Wages Act (M.G.L. c. 151 § 1 et. seq.), the Massachusetts Fair Employment Practices Act (M.G.L. c. 151B), the Massachusetts
Parental Leave Act (M.G.L. c. 149, § 105D), the Massachusetts Small Necessities Leave Act (M.G.L. c. 149, § 52D), the Massachusetts Earned Sick Time Law (M.G.L. c. 149, § 148C), the Massachusetts Domestic Violence Leave
Act (M.G.L. c. 149, § 59E), the Massachusetts Civil Rights Act (M.G.L. c. 12, § 11H et seq.), the Massachusetts Equal Rights Act (M.G.L. c. 93, § 102 et seq.), the Massachusetts Equal Pay Act (M.G.L. c. 149,
§ 105A et seq.), the Massachusetts Law Against Sexual Harassment (M.G.L. c. 214, § 1C et seq.), and the Massachusetts Law Against Retaliation (M.G.L. c. 19C, § 11. et seq.), all as amended. 

Virginia: any Virginia state or local laws, administrative rules or regulations respecting employment, including but not limited to,
the Virginia Payment of Wage Law (VA Code Ann., § 40.1-29, et seq.), Virginia Minimum Wage Act (VA Code Ann., §§ 40.1-28.8 - 40.1-28.12), Virginia Right-to-Work Law (VA Code Ann.,
§ 40.1-58 - 40.1-69), Virginia Prevention of Employment Law (VA Code Ann.,
§ 40.1-27), Virginia Equal Pay Law (VA Code Ann., § 40.1-28.6); Virginia Human Rights Act (VA Code Ann.,
§ 2.2-3900, et seq.) and the Virginians with Disabilities Act (VA Code Ann. § 51.5-41, et seq.), all as amended. 

Please note that General Release of Claims specifically includes a waiver and release of Claims that you have or may have regarding
payments or amounts covered by the Massachusetts Wage Act, Massachusetts Minimum Fair Wages Act, and all other applicable state minimum wage and wage payment laws (including, for instance, hourly wages, salary, overtime, minimum wages, commissions,
vacation pay, holiday pay, sick leave pay, dismissal pay, bonus pay or severance pay), as well as Claims for retaliation under these Acts. 

IMPORTANT NOTE: This list is not intended to an exhaustive list of all states covered by the General Release and/or all statutes in the
above referenced states, to which the General Release applies.Exhibit 4.5

    

    
      
        HEARTLAND MEDIA ACQUISITION CORP.

        DESCRIPTION OF SECURITIES

      

      
        

        

        Pursuant to our amended and restated certificate of incorporation, our authorized capital stock consists of 250,000,000 shares of Class A common stock, $0.0001 par value, 25,000,000 shares of
          Class B common stock, $0.0001 par value, and 2,500,000 shares of undesignated preferred stock, $0.0001 par value. The following description summarizes the material terms of our securities. Because it is only a summary, it may not contain all the
          information that is important to you.

      

      
        

        

        Units

      

      
        

        

        Each unit consists of one share of Class A common stock and one-half of one redeemable warrant. Each warrant entitles the holder thereof to purchase one share of Class A common stock at a price
          of $11.50 per share, subject to adjustment as described in our final prospectus filed with the Securities and Exchange Commission (the “SEC”) on January 24, 2022. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only
          for a whole number of shares of Class A common stock. This means that only a whole warrant may be exercised at any given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will
          trade. Accordingly, unless you purchase at least two units, you will not be able to receive or trade a whole warrant.

      

      
        

        

        Common Stock

      

      
        

        

        Only holders of Class B common stock will have the right to elect directors or remove directors prior to the completion of our initial business combination. These provisions in our amended and
          restated certificate of incorporation may only be amended by a resolution passed by the holders of a majority of our Class B common stock. Holders of the Class A common stock and holders of the Class B common stock of record are entitled to one
          vote for each share held on all other matters to be voted on by stockholders, including any vote in connection with our initial business combination, and vote together as a single class, except as required by law or the applicable rules of the
          New York Stock Exchange (the “NYSE”).

        

        

        Unless specified in our amended and restated certificate of incorporation or bylaws, or as required by applicable provisions of the Delaware General Corporation Law (the “DGCL”) or applicable
          stock exchange rules, the affirmative vote of a majority of our common stock that are voted is required to approve any such matter voted on by our stockholders. Our board of directors is divided into three classes, each of which will generally
          serve for a term of three years with only one class of directors being elected in each year. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the founder shares voted
          for the election of directors can elect all of the directors prior to our initial business combination. Our stockholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available
          therefor.

        

        

        Because our amended and restated certificate of incorporation authorizes the issuance of up to 250,000,000 shares of Class A common stock, if we were to enter into a business combination, we may
          (depending on the terms of such a business combination) be required to increase the number of shares of common stock which we are authorized to issue at the same time as our stockholders vote on the business combination to the extent we seek
          stockholder approval in connection with our initial business combination.

        

        

        Under Section 211(b) of the DGCL, we are, however, required to hold an annual meeting of stockholders for the purposes of electing directors in accordance with our bylaws unless such election is
          made by written consent in lieu of such a meeting. We may not hold an annual meeting of stockholders to elect new directors prior to the consummation of our initial business combination (unless required by the NYSE), and thus we may not be in
          compliance with Section 211(b) of the DGCL, which requires an annual meeting. Therefore, if our stockholders want us to hold an annual meeting prior to the consummation of our initial business combination, they may attempt to force us to hold one
          by submitting an application to the Delaware Court of Chancery in accordance with Section 211(c) of the DGCL.

         

        

      

      
        
          

      

      
      
        We will provide our public stockholders with the opportunity to redeem all or a portion of their shares upon the completion of our initial business combination at a per-share price, payable in
          cash, equal to the aggregate amount then on deposit in the trust account as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account (net of taxes
          payable), divided by the number of then outstanding public shares, subject to the limitations described herein. The per-share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting
          commissions we will pay to the underwriters. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to any founder shares and any public
          shares held by them in connection with the completion of our initial business combination. Permitted transferees of our sponsor, officers or directors will be subject to the same obligations.

        

        

        Unlike some other blank check companies that hold stockholder votes and conduct proxy solicitations in conjunction with their initial business combinations and provide for related redemptions of
          public shares for cash upon completion of such initial business combinations even when a vote is not required by applicable law or stock exchange rules, if a stockholder vote is not required by applicable law or stock exchange rules and we do not
          decide to hold a stockholder vote for business or other reasons, we will, pursuant to our amended and restated certificate of incorporation, conduct the redemptions pursuant to the tender offer rules of the SEC, and file tender offer documents
          with the SEC prior to completing our initial business combination. Our amended and restated certificate of incorporation requires these tender offer documents to contain substantially the same financial and other information about the initial
          business combination and the redemption rights as is required under the SEC’s proxy rules. If, however, a stockholder approval of the transaction is required by applicable law or stock exchange rules, or we decide to obtain stockholder approval
          for business or other reasons, we will, like many blank check companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If we seek stockholder approval, we
          will complete our initial business combination only if a majority of the outstanding shares of common stock voted are voted in favor of the business combination. A quorum for such meeting will consist of the holders present in person or by proxy
          of shares of outstanding capital stock of the company representing a majority of the voting power of all outstanding shares of capital stock of the company entitled to vote at such meeting. However, the participation of our sponsor, officers,
          directors, advisors or any of their affiliates in privately-negotiated transactions (as described in our final prospectus filed with the SEC on January 24, 2022), if any, could result in the approval of our initial business combination even if a
          majority of our public stockholders vote, or indicate their intention to vote, against such business combination. For purposes of seeking approval of the majority of our outstanding shares of common stock, non-votes will have no effect on the
          approval of our initial business combination once a quorum is obtained. We intend to give approximately30 days (but not less than 10 days nor more than 60 days) prior written notice of any such meeting, if required, at which a vote shall be taken
          to approve our business combination. These quorum and voting thresholds, and the voting agreements of our sponsor, may make it more likely that we will consummate our initial business combination.

        

        

        If we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our
          amended and restated certificate of incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13
          of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of our public shares, which we refer to as the “Excess Shares,” without our prior
          consent. However, we would not be restricting our stockholders’ ability to vote all of their shares (including Excess Shares) for or against our initial business combination. Our stockholders’ inability to redeem the Excess Shares will reduce
          their influence over our ability to complete our initial business combination, and such stockholders could suffer a material loss in their investment if they sell such Excess Shares on the open market. Additionally, such stockholders will not
          receive redemption distributions with respect to the Excess Shares if we complete the business combination, and, as a result, such stockholders will continue to hold that number of shares exceeding 15% and, in order to dispose such shares would
          be required to sell their stock in open market transactions, potentially at a loss.

         

        

      

      
        2

        
          

      

      
        If we seek stockholder approval in connection with our initial business combination, our sponsor, officers and directors have agreed (and their permitted transferees will agree), pursuant to the
          terms of a letter agreement entered into with us, to vote any founder shares and any public shares held by them in favor of our initial business combination. As a result, in addition to the founder shares, we would need 7,217,600, or 37.5%
          (assuming all outstanding shares are voted), or 1,202,935, or 6.25% (assuming only the minimum number of shares representing a quorum are voted), of the 19,246,931 public shares sold in our initial public offering to be voted in favor of our
          initial business combination in order to have such initial business combination approved. Additionally, each public stockholder may elect to redeem its public shares without voting and, if they do vote, irrespective of whether they vote for or
          against the proposed transaction.

        

        

        Pursuant to our amended and restated certificate of incorporation, if we have not completed our initial business combination within 18 months from the closing of our initial public offering or up
          to 21 months from the closing of our initial public offering at our election, subject to certain conditions, including the deposit of $1,750,000 (or $0.10 per unit) into the trust account (any extended time period beyond the initial 18 month
          period, an “Extension Period”), we will: (1) cease all operations except for the purpose of winding up; (2) as promptly as reasonably possible but not more than 10 business days thereafter, redeem 100% of the public shares, at a per-share price,
          payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes payable and less up to $100,000 of interest to pay dissolution expenses), divided
          by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any); and (3) as promptly as reasonably
          possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of creditors and the
          requirements of other applicable law. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have waived their rights to liquidating distributions from the trust account with respect to any
          founder shares held by them if we fail to complete our initial business combination within 18 months from the closing of our initial public offering or during any Extension Period. However, if our sponsor, officers and directors acquire public
          shares after our initial public offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete our initial business combination within the allotted 18-month time
          period or during any Extension Period.

        

        

        In the event of a liquidation, dissolution or winding up of the company after a business combination, our stockholders are entitled to share ratably in all assets remaining available for
          distribution to them after payment of liabilities and after provision is made for each class of stock, if any, having preference over the common stock. Our stockholders have no preemptive or other subscription rights. There are no sinking fund
          provisions applicable to the common stock, except that we will provide our stockholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the trust account,
          including interest (which interest shall be net of taxes payable), upon the completion of our initial business combination, subject to the limitations described herein.

      

      
        

        

        Warrants

        

        

      

      
        Each whole warrant entitles the registered holder to purchase one share of Class A common stock at a price of $11.50 per whole share, subject to adjustment as discussed below, at any time
          commencing on the later of 12 months from the closing of our initial public offering and 30 days after the completion of our initial business combination, except as described below. Pursuant to the warrant agreement, a warrant holder may exercise
          its warrants only for a whole number of shares of Class A common stock. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole
          warrants will trade. Accordingly, unless you purchase at least two units, you will not be able to receive or trade a whole warrant. The warrants will expire five years after the completion of our initial business combination, at 5:00 p.m., New
          York City time, or earlier upon redemption or liquidation.

        

        

        We will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a
            warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act of 1933, as amended (the
              “Securities Act”), covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class A common stock is available, subject to our
              satisfying our obligations with respect to registration, or such warrant may be exercised on a cashless basis in accordance with the terms of the warrant agreement. No warrant will be exercisable for cash or on a cashless basis, and we will
              not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an
              exemption is available. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may
              have no value and may expire worthless. In no event will we be required to net cash settle any warrants. In the event that a warrant is not exercisable, the purchaser of a unit containing such warrant will have paid the full purchase price
              for the unit solely for the share of Class A common stock underlying such unit.

         

            

      

      
        3

        
          

      

      
        We have agreed that as soon as practicable, but in no event later than 20 business days after the closing of our initial business combination, we will use our commercially reasonable efforts to
          file with the SEC a registration statement registering the issuance, under the Securities Act, of the shares of Class A common stock issuable upon exercise of the warrants. We will use our commercially reasonable efforts to cause the same to
          become effective within 60 business days after the closing of our initial business combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the redemption or expiration of the
          warrants in accordance with the provisions of the warrant agreement. Notwithstanding the above, if our Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange and, as such, does not satisfy
          the definition of a “covered security” under Section 18(b)(1) of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the
          Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement, but will use our commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the
          extent an exemption is not available. If a registration statement covering the shares of our Class A common stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial business
          combination, warrant holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in
          accordance with Section 3(a)(9) of the Securities Act or another exemption. In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of Class A common stock equal to the lesser of (A) the
          quotient obtained by dividing (x) the product of the number of shares of Class A common stock underlying the warrants, multiplied by the excess of the “fair market value” of our Class A common stock over the exercise price of the warrants by (y)
          the fair market value and (B) the product of 0.361 and the number of warrants surrendered by such holder, subject to adjustment. The “fair market value” as used in this paragraph shall mean the average of the volume-weighted average price of the
          Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of exercise is received by the warrant agent.

        

        

        Redemption of warrants when the price per share of Class A common stock equals or
            exceeds $18.00. Once the warrants become exercisable, we may redeem the outstanding warrants:

      

       

      	

            	•	
              in whole and not in part;

            

       

      	

            	•	
              at a price of $0.01 per warrant;

            

       

      	

            	•	
              upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and

            

       

      	

            	•	
              if, and only if, the last reported sale price of the shares of our Class A common stock for any 20 trading days within a 30-trading day period ending three business days before we send to the notice of
                redemption to the warrant holders (which we refer to as the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like and certain issuances of Class
                A common stock and equity-linked securities).

            

      
        

        

      

      
        We will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of
          the warrants is then effective and a current prospectus relating to those shares of common stock is available throughout the 30 day redemption period or we require the exercise of the warrants on a cashless basis as described below. If and when
          the warrants become redeemable by us, we may exercise our redemption right even if the issuance of the underlying securities is not exempt under all applicable state securities laws and we are unable to register or qualify the underlying
          securities for sale under all such laws. As a result, we may redeem the warrants as set forth above even if the holders are otherwise unable to exercise the warrants.

         

        

      

      
        4

        
          

      

      

      
        We have established the $18.00 redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If
          the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class A common
          stock may fall below the $18.00 redemption trigger price (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like and for certain issuances of Class A common stock and equity-linked securities as described
          below) as well as the $11.50 warrant exercise price after the redemption notice is issued.

        

        

        If we call the warrants for redemption as described above, our management will have the option to require any holder that wishes to exercise his, her or its warrant to do so on a “cashless
          basis.” In determining whether to require all holders to exercise their warrants on a “cashless basis,” our management will consider, among other factors, our cash position, the number of warrants that are outstanding and the dilutive effect on
          our stockholders of issuing the maximum number of shares of Class A common stock issuable upon the exercise of our warrants. If our management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering
          their warrants for that number of shares of Class A common stock equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of shares of Class A common stock underlying the warrants, multiplied by the excess of the
          “fair market value” (defined below) over the exercise price of the warrants by (y) the fair market value and (B) the product of 0.361 and the number of warrants surrendered by the holder, subject to adjustment. The “fair market value” shall mean
          the volume-weighted average price of the Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. If our management takes advantage of
          this option, the notice of redemption will contain the information necessary to calculate the number of shares of Class A common stock to be received upon exercise of the warrants, including the “fair market value” in such case. Requiring a
          cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to us if we do not need the cash from the exercise of
          the warrants after our initial business combination. If we call our warrants for redemption and our management does not take advantage of this option, our sponsor and its permitted transferees would still be entitled to exercise their private
          placement warrants for cash or on a cashless basis using the same formula described above that other warrant holders would have been required to use had all warrant holders been required to exercise their warrants on a cashless basis.

        

        

        Redemption of warrants when the price per share of Class A common stock equals or
            exceeds $10.00. Once the warrants become exercisable, we may redeem the outstanding warrants:

      

       

      	

            	•	
              in whole and not in part;

            

       

      	

            	•	
              at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption to each warrant holder provided that holders will be able to exercise their warrants on a cashless basis prior to redemption
                and receive that number of shares determined by reference to the table below, based on the redemption date and the “fair market value” of our Class A common stock (as defined below) except as otherwise described below;

            

       

      	

            	•	
              if, and only if, the Reference Value (as defined above under “Redemption of Warrants When the Price per Share of Our Class A Common Stock Equals or Exceeds $18.00”) equals or exceeds $10.00 per share (as
                adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like and certain issuances of Class A common stock and equity-linked securities); and

            

       

      	

            	•	
              if the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like and certain issuances of
                Class A common stock and equity-linked securities), the private warrants must also be concurrently called for redemption on the same terms (except as described above with respect to a holder’s ability to cashless exercise its warrants) as
                the outstanding public warrants, as described above.

            

      
        

        

        Beginning on the date the notice of redemption is given until the warrants are redeemed or exercised, holders may elect to exercise their warrants on a cashless basis. We will not redeem the
          warrants as described above unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those
          shares of common stock is available throughout the 30-day redemption period. If and when the warrants become redeemable by us, we may exercise our redemption right even if the issuance of the underlying securities is not exempt under all
          applicable state securities laws and we are unable to register or qualify the underlying securities for sale under all such laws. As a result, we may redeem the warrants as set forth above even if the holders are otherwise unable to exercise the
          warrants.

         

        

      

      
        5

        
          

      

      
        The numbers in the table below represent the number of shares of Class A common stock that a warrant holder will receive upon exercise in connection with a redemption by us pursuant to this
          redemption feature, based on the “fair market value” of our Class A common stock on the corresponding redemption date (assuming holders elect to exercise their warrants and such warrants are not redeemed for $0.10 per warrant), determined based
          on the volume-weighted average price of our Class A common stock for the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants, and the number of months that the corresponding
          redemption date precedes the expiration date of the warrants, each as set forth in the table below. We will provide our warrant holders with the final fair market value no later than one business day after the 10-trading day period described
          above ends.

        

        

        Pursuant to the warrant agreement, references above to Class A common stock shall include a security other than Class A common stock into which the Class A common stock has been converted or
          exchanged for in the event we are not the surviving company in our initial business combination. The numbers in the table below will not be adjusted when determining the number of shares of Class A common stock to be issued upon exercise of the
          warrants if we are not the surviving entity following our initial business combination.

        

        

        The stock prices set forth in the column headings of the table below will be adjusted as of any date on which the number of shares issuable upon exercise of a warrant is adjusted as set forth in
          the first three paragraphs under the heading “—Anti-dilution Adjustments” below. The adjusted stock prices in the column headings will equal the stock prices immediately prior to such adjustment, multiplied by a fraction, the numerator of which
          is the number of shares deliverable upon exercise of a warrant immediately prior to such adjustment and the denominator of which is the number of shares deliverable upon exercise of a warrant as so adjusted. The number of shares in the table
          below shall be adjusted in the same manner and at the same time as the number of shares issuable upon exercise of a warrant. If the exercise price of a warrant is adjusted, (a) in the case of an adjustment pursuant to the fifth paragraph under
          the heading “Anti-Dilution Adjustments” below, the adjusted stock prices in the column headings will equal the unadjusted stock price multiplied by a fraction, the numerator of which is the higher of the market value and the newly issued price as
          set forth under the heading “Anti-Dilution Adjustments” and the denominator of which is $10.00 and (b) in the case of an adjustment pursuant to the second paragraph under the heading “Anti-Dilution Adjustments” below, the adjusted stock prices in
          the column headings will equal the unadjusted stock price less the decrease in the exercise price of a warrant pursuant to such exercise price adjustment.

         

        

      

      	
              Redemption date (period to

              expiration of warrants)

            	
              ​

            	
              ​

            	
              Fair market value of Class A common stock

            
	
              ​

            	
              ≤10.00

            	
              ​

            	
              ​

            	
              11.00

            	
              ​

            	
              ​

            	
              12.00

            	
              ​

            	
              ​

            	
              13.00

            	
              ​

            	
              ​

            	
              14.00

            	
              ​

            	
              ​

            	
              15.00

            	
              ​

            	
              ​

            	
              16.00

            	
              ​

            	
              ​

            	
              17.00

            	
              ​

            	
              ​

            	
              ≥18.00

            
	
              60 months

            	
              ​

            	
              ​

            	
              0.261

            	
              ​

            	
              ​

            	
              0.281

            	
              ​

            	
              ​

            	
              0.297

            	
              ​

            	
              ​

            	
              0.311

            	
              ​

            	
              ​

            	
              0.324

            	
              ​

            	
              ​

            	
              0.337

            	
              ​

            	
              ​

            	
              0.348

            	
              ​

            	
              ​

            	
              0.358

            	
              ​

            	
              ​

            	
              0.361

            
	
              57 months

            	
              ​

            	
              ​

            	
              0.257

            	
              ​

            	
              ​

            	
              0.277

            	
              ​

            	
              ​

            	
              0.294

            	
              ​

            	
              ​

            	
              0.310

            	
              ​

            	
              ​

            	
              0.324

            	
              ​

            	
              ​

            	
              0.337

            	
              ​

            	
              ​

            	
              0.348

            	
              ​

            	
              ​

            	
              0.358

            	
              ​

            	
              ​

            	
              0.361

            
	
              54 months

            	
              ​

            	
              ​

            	
              0.252

            	
              ​

            	
              ​

            	
              0.272

            	
              ​

            	
              ​

            	
              0.291

            	
              ​

            	
              ​

            	
              0.307

            	
              ​

            	
              ​

            	
              0.322

            	
              ​

            	
              ​

            	
              0.335

            	
              ​

            	
              ​

            	
              0.347

            	
              ​

            	
              ​

            	
              0.357

            	
              ​

            	
              ​

            	
              0.361

            
	
              51 months

            	
              ​

            	
              ​

            	
              0.246

            	
              ​

            	
              ​

            	
              0.268

            	
              ​

            	
              ​

            	
              0.287

            	
              ​

            	
              ​

            	
              0.304

            	
              ​

            	
              ​

            	
              0.320

            	
              ​

            	
              ​

            	
              0.333

            	
              ​

            	
              ​

            	
              0.346

            	
              ​

            	
              ​

            	
              0.357

            	
              ​

            	
              ​

            	
              0.361

            
	
              48 months

            	
              ​

            	
              ​

            	
              0.241

            	
              ​

            	
              ​

            	
              0.263

            	
              ​

            	
              ​

            	
              0.283

            	
              ​

            	
              ​

            	
              0.301

            	
              ​

            	
              ​

            	
              0.317

            	
              ​

            	
              ​

            	
              0.332

            	
              ​

            	
              ​

            	
              0.344

            	
              ​

            	
              ​

            	
              0.356

            	
              ​

            	
              ​

            	
              0.361

            
	
              45 months

            	
              ​

            	
              ​

            	
              0.235

            	
              ​

            	
              ​

            	
              0.258

            	
              ​

            	
              ​

            	
              0.279

            	
              ​

            	
              ​

            	
              0.298

            	
              ​

            	
              ​

            	
              0.315

            	
              ​

            	
              ​

            	
              0.330

            	
              ​

            	
              ​

            	
              0.343

            	
              ​

            	
              ​

            	
              0.356

            	
              ​

            	
              ​

            	
              0.361

            
	
              42 months

            	
              ​

            	
              ​

            	
              0.228

            	
              ​

            	
              ​

            	
              0.252

            	
              ​

            	
              ​

            	
              0.274

            	
              ​

            	
              ​

            	
              0.294

            	
              ​

            	
              ​

            	
              0.312

            	
              ​

            	
              ​

            	
              0.328

            	
              ​

            	
              ​

            	
              0.342

            	
              ​

            	
              ​

            	
              0.355

            	
              ​

            	
              ​

            	
              0.361

            
	
              39 months

            	
              ​

            	
              ​

            	
              0.221

            	
              ​

            	
              ​

            	
              0.246

            	
              ​

            	
              ​

            	
              0.269

            	
              ​

            	
              ​

            	
              0.290

            	
              ​

            	
              ​

            	
              0.309

            	
              ​

            	
              ​

            	
              0.325

            	
              ​

            	
              ​

            	
              0.340

            	
              ​

            	
              ​

            	
              0.354

            	
              ​

            	
              ​

            	
              0.361

            
	
              36 months

            	
              ​

            	
              ​

            	
              0.213

            	
              ​

            	
              ​

            	
              0.239

            	
              ​

            	
              ​

            	
              0.263

            	
              ​

            	
              ​

            	
              0.285

            	
              ​

            	
              ​

            	
              0.305

            	
              ​

            	
              ​

            	
              0.323

            	
              ​

            	
              ​

            	
              0.339

            	
              ​

            	
              ​

            	
              0.353

            	
              ​

            	
              ​

            	
              0.361

            
	
              33 months

            	
              ​

            	
              ​

            	
              0.205

            	
              ​

            	
              ​

            	
              0.232

            	
              ​

            	
              ​

            	
              0.257

            	
              ​

            	
              ​

            	
              0.280

            	
              ​

            	
              ​

            	
              0.301

            	
              ​

            	
              ​

            	
              0.320

            	
              ​

            	
              ​

            	
              0.337

            	
              ​

            	
              ​

            	
              0.352

            	
              ​

            	
              ​

            	
              0.361

            
	
              30 months

            	
              ​

            	
              ​

            	
              0.196

            	
              ​

            	
              ​

            	
              0.224

            	
              ​

            	
              ​

            	
              0.250

            	
              ​

            	
              ​

            	
              0.274

            	
              ​

            	
              ​

            	
              0.297

            	
              ​

            	
              ​

            	
              0.316

            	
              ​

            	
              ​

            	
              0.335

            	
              ​

            	
              ​

            	
              0.351

            	
              ​

            	
              ​

            	
              0.361

            
	
              27 months

            	
              ​

            	
              ​

            	
              0.185

            	
              ​

            	
              ​

            	
              0.214

            	
              ​

            	
              ​

            	
              0.242

            	
              ​

            	
              ​

            	
              0.268

            	
              ​

            	
              ​

            	
              0.291

            	
              ​

            	
              ​

            	
              0.313

            	
              ​

            	
              ​

            	
              0.332

            	
              ​

            	
              ​

            	
              0.350

            	
              ​

            	
              ​

            	
              0.361

            
	
              24 months

            	
              ​

            	
              ​

            	
              0.173

            	
              ​

            	
              ​

            	
              0.204

            	
              ​

            	
              ​

            	
              0.233

            	
              ​

            	
              ​

            	
              0.260

            	
              ​

            	
              ​

            	
              0.285

            	
              ​

            	
              ​

            	
              0.308

            	
              ​

            	
              ​

            	
              0.329

            	
              ​

            	
              ​

            	
              0.348

            	
              ​

            	
              ​

            	
              0.361

            
	
              21 months

            	
              ​

            	
              ​

            	
              0.161

            	
              ​

            	
              ​

            	
              0.193

            	
              ​

            	
              ​

            	
              0.223

            	
              ​

            	
              ​

            	
              0.252

            	
              ​

            	
              ​

            	
              0.279

            	
              ​

            	
              ​

            	
              0.304

            	
              ​

            	
              ​

            	
              0.326

            	
              ​

            	
              ​

            	
              0.347

            	
              ​

            	
              ​

            	
              0.361

            
	
              18 months

            	
              ​

            	
              ​

            	
              0.146

            	
              ​

            	
              ​

            	
              0.179

            	
              ​

            	
              ​

            	
              0.211

            	
              ​

            	
              ​

            	
              0.242

            	
              ​

            	
              ​

            	
              0.271

            	
              ​

            	
              ​

            	
              0.298

            	
              ​

            	
              ​

            	
              0.322

            	
              ​

            	
              ​

            	
              0.345

            	
              ​

            	
              ​

            	
              0.361

            
	
              15 months

            	
              ​

            	
              ​

            	
              0.130

            	
              ​

            	
              ​

            	
              0.164

            	
              ​

            	
              ​

            	
              0.197

            	
              ​

            	
              ​

            	
              0.230

            	
              ​

            	
              ​

            	
              0.262

            	
              ​

            	
              ​

            	
              0.291

            	
              ​

            	
              ​

            	
              0.317

            	
              ​

            	
              ​

            	
              0.342

            	
              ​

            	
              ​

            	
              0.361

            
	
              12 months

            	
              ​

            	
              ​

            	
              0.111

            	
              ​

            	
              ​

            	
              0.146

            	
              ​

            	
              ​

            	
              0.181

            	
              ​

            	
              ​

            	
              0.216

            	
              ​

            	
              ​

            	
              0.250

            	
              ​

            	
              ​

            	
              0.282

            	
              ​

            	
              ​

            	
              0.312

            	
              ​

            	
              ​

            	
              0.339

            	
              ​

            	
              ​

            	
              0.361

            
	
              9 months

            	
              ​

            	
              ​

            	
              0.090

            	
              ​

            	
              ​

            	
              0.125

            	
              ​

            	
              ​

            	
              0.162

            	
              ​

            	
              ​

            	
              0.199

            	
              ​

            	
              ​

            	
              0.237

            	
              ​

            	
              ​

            	
              0.272

            	
              ​

            	
              ​

            	
              0.305

            	
              ​

            	
              ​

            	
              0.336

            	
              ​

            	
              ​

            	
              0.361

            
	
              6 months

            	
              ​

            	
              ​

            	
              0.065

            	
              ​

            	
              ​

            	
              0.099

            	
              ​

            	
              ​

            	
              0.137

            	
              ​

            	
              ​

            	
              0.178

            	
              ​

            	
              ​

            	
              0.219

            	
              ​

            	
              ​

            	
              0.259

            	
              ​

            	
              ​

            	
              0.296

            	
              ​

            	
              ​

            	
              0.331

            	
              ​

            	
              ​

            	
              0.361

            
	
              3 months

            	
              ​

            	
              ​

            	
              0.034

            	
              ​

            	
              ​

            	
              0.065

            	
              ​

            	
              ​

            	
              0.104

            	
              ​

            	
              ​

            	
              0.150

            	
              ​

            	
              ​

            	
              0.197

            	
              ​

            	
              ​

            	
              0.243

            	
              ​

            	
              ​

            	
              0.286

            	
              ​

            	
              ​

            	
              0.326

            	
              ​

            	
              ​

            	
              0.361

            
	
              0 months

            	
              ​

            	
              ​

            	
              —

            	
              ​

            	
              ​

            	
              —

            	
              ​

            	
              ​

            	
              0.042

            	
              ​

            	
              ​

            	
              0.115

            	
              ​

            	
              ​

            	
              0.179

            	
              ​

            	
              ​

            	
              0.233

            	
              ​

            	
              ​

            	
              0.281

            	
              ​

            	
              ​

            	
              0.323

            	
              ​

            	
              ​

            	
              0.361

            

      
        

        

        
          6

          
            

        

        The exact fair market value and time to expiration may not be set forth in the table above, in which case, if the fair market value is between two values in the table or the redemption date is
          between two redemption dates in the table, the number of shares of Class A common stock to be issued for each warrant exercised will be determined by a straight-line interpolation between the number of shares set forth for the higher and lower
          fair market values and the earlier and later redemption dates, as applicable, based on a 365 or 366-day year, as applicable. For example, if the volume-weighted average price of our Class A common stock for the 10 trading days immediately
          following the date on which the notice of redemption is sent to the holders of warrants is $11.00 per share, and at such time there are 57 months until the expiration of the warrants, holders may choose to, in connection with this redemption
          feature, exercise their warrants for 0.277 shares of Class A common stock for each whole warrant. For an example where the exact fair market value and redemption date are not as set forth in the table above, if the volume-weighted average price
          of our Class A common stock for the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants is $13.50 per share, and at such time there are 38 months until the expiration of the
          warrants, holders may choose to, in connection with this redemption feature, exercise their warrants for 0.298 shares of Class A common stock for each whole warrant. In no event will the warrants be exercisable in connection with this redemption
          feature for more than 0.361 shares of Class A common stock per warrant, subject to adjustment. Finally, as reflected in the table above, if the warrants are out of the money and about to expire, they cannot be exercised on a cashless basis in
          connection with a redemption by us pursuant to this redemption feature, since they will not be exercisable for any shares of Class A common stock.

        

        

        This redemption feature differs from the typical warrant redemption features used in other blank check offerings, which typically only provide for a redemption of warrants for cash (other than
          the private placement warrants) when the trading price for the Class A common stock exceeds $18.00 per share for a specified period of time. This redemption feature is structured to allow for all of the outstanding warrants to be redeemed when
          the Class A common stock is trading at or above $10.00 per share, which may be at a time when the trading price of our Class A common stock is below the exercise price of the warrants. We have established this redemption feature to provide us
          with the flexibility to redeem the warrants without the warrants having to reach the $18.00 per share threshold set forth above under “—Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00.” Holders
          choosing to exercise their warrants in connection with a redemption pursuant to this feature will, in effect, receive a number of shares for their warrants based on an option pricing model with a fixed volatility input as of the date of our final
          prospectus. This redemption right provides us with an additional mechanism by which to redeem all of the outstanding warrants, and therefore have certainty as to our capital structure as the warrants would no longer be outstanding and would have
          been exercised or redeemed and we will be required to pay the redemption price to warrant holders if we choose to exercise this redemption right and it will allow us to quickly proceed with a redemption of the warrants if we determine it is in
          our best interest to do so. As such, we would redeem the warrants in this manner when we believe it is in our best interest to update our capital structure to remove the warrants and pay the redemption price to the warrant holders.

         

        

      

      
        7

        
          

      

      
        As stated above, we can redeem the warrants when the Class A common stock is trading at a price starting at $10.00, which is below the exercise price of $11.50, because it will provide certainty
          with respect to our capital structure and cash position while providing warrant holders with the opportunity to exercise their warrants on a cashless basis for the applicable number of shares. If we choose to redeem the warrants when the Class A
          common stock is trading at a price below the exercise price of the warrants, this could result in the warrant holders receiving fewer shares of Class A common stock than they would have received if they had chosen to wait to exercise their
          warrants for Class A common stock if and when such Class A common stock trades at a price higher than the exercise price of $11.50 per share.

        

        

        No fractional shares of Class A common stock will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, we will round down to the
          nearest whole number of the number of shares of Class A common stock to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the shares of Class A common stock pursuant to the warrant
          agreement (for instance, if we are not the surviving company in our initial business combination), the warrants may be exercised for such security.

        

        

        At such time as the warrants become exercisable for a security other than the shares of our Class A common stock, we (or the surviving company) will use our commercially reasonable efforts to
          register under the Securities Act the security issuable upon exercise of the warrants.

        

        

        Holder Restriction on Warrant Exercise. A holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such
            person (together with such person’s affiliates), to the warrant agent’s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (or such other amount as a holder may specify) of the shares of Class A common stock outstanding
            immediately after giving effect to such exercise.

        

        

        Anti-dilution Adjustments. If the
            number of outstanding shares of Class A common stock is increased by a stock dividend payable in shares of Class A common stock, or by a split-up of shares of Class A common stock or other similar event, then, on the effective date of such
            stock dividend, split-up or similar event, the number of shares of Class A common stock issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding shares of Class A common stock. A rights offering
            to holders of Class A common stock entitling holders to purchase shares of Class A common stock at a price less than the fair market value will be deemed a stock dividend of a number of shares of Class A common stock equal to the product of (1)
            the number of shares of Class A common stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class A common stock) multiplied by (2)
            one minus the quotient of (x) the price per share of Class A common stock paid in such rights offering divided by (y) the fair market value. For these purposes (1) if the rights offering is for securities convertible into or exercisable for
            Class A common stock, in determining the price payable for Class A common stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (2) fair
            market value means the volume-weighted average price of Class A common stock as reported during the ten trading day period ending on the trading day prior to the first date on which the shares of Class A common stock trade on the applicable
            exchange or in the applicable market, regular way, without the right to receive such rights.

        

        

        In addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of Class A common stock
          on account of such shares of Class A common stock (or other shares of our capital stock into which the warrants are convertible), other than (a) as described above, (b) certain ordinary cash dividends (initially defined as up to $0.50 per share
          in a 365 day period), (c) to satisfy the redemption rights of the holders of Class A common stock in connection with a proposed initial business combination, (d) to satisfy the redemption rights of the holders of Class A common stock in
          connection with a stockholder vote to amend our amended and restated certificate of incorporation (i) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of
          our Class A common stock if we do not complete our initial business combination within 18 months from the closing of our initial public offering or during any Extension Period or (ii) with respect to any other provision relating to stockholders’
          rights or pre-initial business combination activity, or (e) in connection with the redemption of our public shares upon our failure to complete our initial business combination, then the warrant exercise price will be decreased, effective
          immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share of Class A common stock in respect of such event.

         

        

      

      
        8

        
          

      

      
        If the number of outstanding shares of our Class A common stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Class A common stock or other
          similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of shares of Class A common stock issuable on exercise of each warrant will be decreased in
          proportion to such decrease in outstanding shares of Class A common stock.

        

        

        Whenever the number of shares of Class A common stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the
          warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of shares of Class A common stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y)
          the denominator of which will be the number of shares of Class A common stock so purchasable immediately thereafter.

        

        

        In addition, if (x) we issue additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination
          at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to our
          sponsor or its affiliates, without taking into account any founder shares held by our sponsor or such affiliates, as applicable, prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total
          equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and (z) the volume-weighted average trading price of
          our Class A common stock during the 20-trading day period starting on the trading day after the day on which we consummate our initial business combination (such price, the “market value”) is below $9.20 per share, then the exercise price of the
          warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the market value and the newly issued price, and the $18.00 per share redemption trigger price described above under “—Redemption of warrants when the price per
          share of Class A common stock equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the market value and the newly issued price, and the $10.00 per share redemption trigger price will be adjusted
          (to the nearest cent) to be equal to the higher of the market value and the newly issued price.

         

        

      

      
        9

        
          

      

      
        In case of any reclassification or reorganization of the outstanding shares of Class A common stock (other than those described above or that solely affects the par value of such shares of Class
          A common stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or
          reorganization of our outstanding shares of Class A common stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with
          which we are dissolved, the holders of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the shares of our Class A common stock
          immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization,
          merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised their warrants immediately prior to such event. However, if such holders were
          entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable upon such consolidation or merger, then the kind and amount of securities, cash or other assets for which each warrant will become
          exercisable will be deemed to be the weighted average of the kind and amount received per share by such holders in such consolidation or merger that affirmatively make such election, and if a tender, exchange or redemption offer has been made to
          and accepted by such holders (other than a tender, exchange or redemption offer made by the company in connection with redemption rights held by stockholders of the company as provided for in the company’s amended and restated certificate of
          incorporation or as a result of the redemption of shares of Class A common stock by the company if a proposed initial business combination is presented to the stockholders of the company for approval) under circumstances in which, upon completion
          of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning of Rule 13d-5(b)(1) under the Exchange Act) of which such maker is a part, and together with any affiliate or associate of such maker
          (within the meaning of Rule 12b-2 under the Exchange Act) and any members of any such group of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act) more than 50% of the
          outstanding shares of Class A common stock, the holder of a warrant will be entitled to receive the highest amount of cash, securities or other property to which such holder would actually have been entitled as a stockholder if such warrant
          holder had exercised the warrant prior to the expiration of such tender or exchange offer, accepted such offer and all of the Class A common stock held by such holder had been purchased pursuant to such tender or exchange offer, subject to
          adjustments (from and after the consummation of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in the warrant agreement. Additionally, if less than 70% of the consideration receivable by the
          holders of Class A common stock in such a transaction is payable in the form of common equity in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be
          so listed for trading or quoted immediately following such event, and if the registered holder of the warrant properly exercises the warrant within thirty days following public disclosure of such transaction, the warrant exercise price will be
          reduced as specified in the warrant agreement based on the per share consideration minus Black-Scholes Warrant Value (as defined in the warrant agreement) of the warrant.

        

        

        The warrants have been issued in registered form under a warrant agreement between Continental Stock Transfer & Trust Company, as warrant agent, and us. You should review a copy of the
          warrant agreement, which is filed as an exhibit to our Annual Report on Form 10-K, for a complete description of the terms and conditions applicable to the warrants. The warrant agreement provides that the terms of the warrants may be amended
          without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 65% of the then outstanding public warrants to make any change that adversely affects the interests
          of the registered holders of public warrants.

        

        

        The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the
          warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of warrants being exercised. The
          warrant holders do not have the rights or privileges of holders of Class A common stock and any voting rights until they exercise their warrants and receive shares of Class A common stock. After the issuance of shares of Class A common stock upon
          exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by holders of Class A common stock.

        

        

        No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

      

      
        

        

        Our Transfer Agent and Warrant Agent

      

      
        

        

        The transfer agent for our common stock and warrant agent for our warrants is Continental Stock Transfer & Trust Company. We have agreed to indemnify Continental Stock Transfer & Trust
          Company in its roles as transfer agent and warrant agent, its agents and each of its stockholders, directors, officers and employees against all liabilities, including judgments, costs and reasonable counsel fees that may arise out of acts
          performed or omitted for its activities in that capacity, except for any liability due to any gross negligence, willful misconduct or bad faith of the indemnified person or entity.

      

      
        

        

        
          10

          
            

        

        Our Amended and Restated Certificate of Incorporation

      

      
        

        

        Our amended and restated certificate of incorporation contains certain requirements and restrictions relating to our initial public offering that will apply to us until the completion of our
          initial business combination. These provisions cannot be amended without the approval of the holders of at least 65% of our common stock. Our initial stockholders may participate in any vote to amend our amended and restated certificate of
          incorporation and will have the discretion to vote in any manner they choose. Specifically, our amended and restated certificate of incorporation provides, among other things, that:

        

        

      

      	

            	•	
              if we have not completed our initial business combination within 18 months from the closing of our initial public offering or up to 21 months from the closing of our initial public offering at our election,
                subject to certain conditions, including the deposit of $1,750,000 (or $0.10 per unit) into the trust account, we will: (1) cease all operations except for the purpose of winding up; (2) as promptly as reasonably possible but not more than
                10 business days thereafter, redeem 100% of the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net
                of taxes payable and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including
                the right to receive further liquidating distributions, if any); and (3) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate,
                subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law;

            

       

      	

            	•	
              if we anticipate that we may not be able to complete our initial business combination within 18 months, we may, by resolution of our board of directors, extend the period of time we will have to complete an
                initial business combination by an additional three months, subject to the deposit of $1,750,000 (or $0.10 per unit) into the trust account. Our public stockholders will not be entitled to vote on, or redeem their shares in connection with,
                any such extension. This feature is different than most other special purpose acquisition companies, in which any extension of the company’s period to consummate an initial business combination would require a vote of the company's public
                stockholders and in connection with such vote, public stockholders would have the right to redeem their public shares;

            

       

      	

            	•	
              prior to our initial business combination, we may not issue additional shares of capital stock that would entitle the holders thereof to (1) receive funds from the trust account or (2) vote as a class with
                our public shares (a) on any initial business combination or (b) to approve an amendment to our amended and restated certificate of incorporation to (x) extend the time we have to consummate a business combination beyond 18 months from the
                closing of our initial public offering or up to 21 months from the closing of our initial public offering at our election, subject to certain conditions, including the deposit of $1,750,000 (or $0.10 per unit) into the trust account, or (y)
                amend the foregoing provisions;

            

       

      	

            	•	
              although we do not intend to enter into a business combination with a target business that is affiliated with our sponsor, our directors or our officers, we are not prohibited from doing so. In the event we
                enter into such a transaction, we, or a committee of independent and disinterested directors, will obtain an opinion from an independent investment banking firm that is a member of FINRA or from an independent entity that commonly renders
                valuation opinions that such a business combination is fair to our company from a financial point of view;

            

       

      	

            	•	
              if a stockholder vote on our initial business combination is not required by applicable law or stock exchange rules and we do not decide to hold a stockholder vote for business or other reasons, we will offer
                to redeem our public shares pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, and will file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial
                and other information about our initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act;

            

       

      	

            	•	
              our initial business combination must be with one or more target businesses that together have an aggregate fair market value equal to at least 80% of the value of the assets held in the trust account
                (excluding the amount of deferred underwriting commissions held in trust and taxes payable on the income earned on the trust account) at the time of our signing a definitive agreement in connection with our initial business combination;

            

       

      	

            	•	
              our initial business combination will be approved by a majority of our disinterested directors;

            

       

      
        11

        
          

      

      	

            	•	
              if our stockholders approve an amendment to our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial
                business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 18 months from the closing of our initial public offering or up to 21 months from the closing of our initial public
                offering at our election, subject to certain conditions, including the deposit of $1,750,000 (or $0.10 per unit) into the trust account or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business
                combination activity, we will provide our public stockholders with the opportunity to redeem all or a portion of their shares of common stock upon such approval at a per-share price, payable in cash, equal to the aggregate amount then on
                deposit in the trust account, including interest earned on the funds held in the trust account, divided by the number of then outstanding public shares; and

            

       

      	

            	•	
              we will not effectuate our initial business combination solely with another blank check company or a similar company with nominal operations.

            

       

      

      
        In addition, our amended and restated certificate of incorporation provides that we will only redeem our public shares so long as (after such redemptions) our net tangible assets will be at least
          $5,000,001, (a) in the case of our initial business combination, either prior to or upon consummation of such initial business combination, or (b) in the case of an amendment to our amended and restated certificate of incorporation (i) to modify
          the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we have not consummated our initial business combination within 18 months from the closing
          of our initial public offering or up to 21 months from the closing of our initial public offering at our election, subject to certain conditions, including the deposit of $1,750,000 (or $0.10 per unit) into the trust account, or (ii) with respect
          to any other provision relating to stockholders’ rights or pre-initial business combination activity, upon such amendment (in each case so that we do not then become subject to the SEC’s “penny stock” rules).

      

      
        

        

        Certain Anti-takeover Provisions of Delaware Law and our Amended and Restated Certificate of Incorporation and Bylaws

      

      
        

        

        We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. This statute prevents certain Delaware corporations, under certain circumstances, from engaging in a
          “business combination” with:

      

       

      	

            	•	
              a stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an “interested stockholder”);

            

       

      	

            	•	
              an affiliate of an interested stockholder; or

            

       

      	

            	•	
              an associate of an interested stockholder, for three years following the date that the stockholder became an interested stockholder.

            

      
        

        

      

      
        A “business combination” includes a merger or sale of more than 10% of our assets. However, the above provisions of Section 203 do not apply if:

      

       

      	

            	•	
              our board of directors approves the transaction that made the stockholder an “interested stockholder,” prior to the date of the transaction;

            

       

      	

            	•	
              after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction
                commenced, other than statutorily excluded shares of common stock; or

            

       

      	

            	•	
              on or subsequent to the date of the transaction, the business combination is approved by our board of directors and authorized at a meeting of our stockholders, and not by written consent, by an affirmative
                vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder.

            

       

      

      
        12

        
          

      

      
        Under certain circumstances, this provision will make it more difficult for a person who would be an “interested stockholder” to effect various business combinations with a corporation for a
          three-year period. This provision may encourage companies interested in acquiring our company to negotiate in advance with our board of directors because the stockholder approval requirement would be avoided if our board of directors approves
          either the business combination or the transaction which results in the stockholder becoming an interested stockholder. These provisions also may have the effect of preventing changes in our board of directors and may make it more difficult to
          accomplish transactions which stockholders may otherwise deem to be in their best interests.

        

        

        Our amended and restated certificate of incorporation provides that the sponsor and its affiliates, any of their respective direct or indirect transferees who hold at least 15% of our outstanding
          common stock after such transfer and any group as to which such persons are party to, do not constitute “interested stockholders” for purposes of this provision.

        

        

        Our amended and restated certificate of incorporation provides that our board of directors is classified into three classes of directors. As a result, in most circumstances, a person can gain
          control of our board only by successfully engaging in a proxy contest at two or more annual meetings.

        

        

        Our authorized but unissued common stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including
          future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control
          of us by means of a proxy contest, tender offer, merger or otherwise.

      

      
        

        

        Exclusive Forum for Certain Lawsuits

      

      
        

        

      

      
        Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall,
          to the fullest extent permitted by law, be the sole and exclusive forum for any (1) derivative action or proceeding brought on behalf of our company, (2) action asserting a claim of breach of a fiduciary duty owed by any director, officer,
          employee or agent of our company to our company or our stockholders, or any claim for aiding and abetting any such alleged breach, (3) action asserting a claim against our company or any director, officer or employee of our company arising
          pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or our bylaws, or (4) action asserting a claim against us or any director, officer or employee of our company governed by the internal affairs doctrine
          except for, as to each of (1) through (4) above, any claim (A) as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not
          consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or (C) arising under the federal
          securities laws, including the Securities Act as to which the Court of Chancery and the federal district court for the District of Delaware shall concurrently be the sole and exclusive forums. Notwithstanding the foregoing, the provisions of this
          paragraph will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America have exclusive jurisdiction. If any action the subject
          matter of which is within the scope of the forum provisions is filed in a court other than a court located within the State of Delaware (a “foreign action”) in the name of any stockholder, such stockholder shall be deemed to have consented to:
          (x) the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the forum provisions (an “enforcement action”), and (y) having service of
          process made upon such stockholder in any such enforcement action by service upon such stockholder’s counsel in the foreign action as agent for such stockholder. Although we believe this provision benefits us by providing increased consistency in
          the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers. Furthermore, the enforceability of choice of forum provisions in other
          companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable.

      

      
        

        

        Special Meeting of Stockholders

      

      
        

        

        Our bylaws provide that special meetings of our stockholders may be called only by a majority vote of our board of directors, by our chief executive officer or by our chair or co-chair, if any.

         

        

      

      
        13

        
          

      

      
        Advance Notice Requirements for Stockholder Proposals and Director Nominations

      

      
        

        

        Our bylaws provide for advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the
          direction of our board of directors or a committee of our board of directors. In order for any matter to be “properly brought” before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain
          information. Generally, to be timely, a stockholder’s notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the immediately preceding annual meeting of
          stockholders. Our bylaws also specify requirements as to the form and content of a stockholder’s notice. Our bylaws allow the chairman of the meeting at a meeting of the stockholders to adopt rules and regulations for the conduct of meetings
          which may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay or discourage a potential acquirer from conducting a solicitation of
          proxies to elect the acquirer’s own slate of directors or otherwise attempting to influence or obtain control of us.

      

      
        

        

        Action by Written Consent

      

      
        

        

        Any action required or permitted to be taken by our common stockholders must be effected by a duly called annual or special meeting of such stockholders and may not be effected by written consent
          of the stockholders other than with respect to our Class B common stock.

      

      
        

        

        Classified Board of Directors

      

      
        

        

        Our board of directors is divided into three classes, Class I, Class II and Class III, with members of each class serving staggered three-year terms. Our amended and restated certificate of
          incorporation provides that the authorized number of directors may be changed only by resolution of the board of directors. Subject to the terms of any preferred stock, any or all of the directors may be removed from office at any time, but only
          for cause and only by the affirmative vote of holders of a majority of the voting power of all then outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single class. Any vacancy on
          our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. However, prior to our initial business combination, only holders of our
          founder shares will have the right to vote on the election of directors. Holders of our public shares will not be entitled to vote on the election of directors during such time. In addition, prior to the completion of an initial business
          combination, holders of a majority of our founder shares may remove a member of the board of directors for any reason and no reason.

      

      
        

        

        Class B Common Stock Consent Right

      

      
        

        

        For so long as any shares of our Class B common stock remain outstanding, we may not, without the prior vote or written consent of the holders of a majority of the shares of our Class B common
          stock then outstanding, voting separately as a single class, amend, alter or repeal any provision of our amended and restated certificate of incorporation, whether by merger, consolidation or otherwise, if such amendment, alteration or repeal
          would alter or change the powers, preferences or relative, participating, optional or other or special rights of the Class B common stock. Any action required or permitted to be taken at any meeting of the holders of our Class B common stock may
          be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of the outstanding Class B common stock having not less than the minimum
          number of votes that would be necessary to authorize or take such action at a meeting at which all shares of our Class B common stock were present and voted.

        

        

        
           

            

          14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]